| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
33 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-58 |
| Cash Flow (TTM) (Millions $) |
36 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Clementia Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development of transformative treatments for rare bone diseases. The company is committed to developing innovative therapies that address the unmet needs of patients suffering from debilitating and life-threatening skeletal disorders.
Clementia Pharmaceuticals specializes in developing targeted treatments for conditions such as fibrodysplasia ossificans progressiva (FOP) and Multiple Osteochondromas (MO), both of which are extremely rare genetic diseases.
The company's primary goal is to improve the quality of life for patients with these conditions, which often cause severe impairments, by advancing the understanding of the underlying pathology and developing therapeutic solutions. They aim to provide effective treatment options and potentially halt or reverse the progression of these bone diseases.
Clementia Pharmaceuticals leverages its expertise in drug development and clinical research to accelerate the development and approval of its therapies. The company collaborates with medical experts, healthcare professionals, and patient advocacy groups to ensure patient-centric approaches and to gain valuable insights for the development of its treatments.
The dedication of Clementia Pharmaceuticals to addressing the unmet medical needs of patients suffering from rare bone diseases makes it a significant player in the field of rare disease therapeutics.
|
%